7,387
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Risperidone induced amenorrhea and galactorrhea in a case of an adolescent patient

, , & | (Reviewing Editor)
Article: 1328819 | Received 19 Dec 2016, Accepted 05 May 2017, Published online: 18 May 2017

References

  • Kim, Y.-K., Kim, L., & Lee, M. S. (1999). Risperidone and associated amenorrhea: A report of 5 cases. The Journal of Clinical Psychiatry, 60, 315–317.10.4088/JCP.v60n0509
  • Kleinberg, D. L., Davis, J. M., De Coster, R., Van Baelen, B., & Brecher, M. (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology, 19, 57–61.
  • Lee, B.-H., Han, C.-S., Kim, K. H., & Kim, Y. K. (2005). Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice, 9, 29–34.10.1080/13651500510014747
  • Mallikaarjun, S., Salazar, D. E., & Bramer, S. L. (2004). Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. The Journal of Clinical Pharmacology, 44, 179–187.10.1177/0091270003261901
  • Mihara, K., Suzuki, A., Kondo, T., Yasui‐Furukori, N., Ono, S., Otani, K., … Inoue, Y. (2001). Relationship betweenTaq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. American Journal of Medical Genetics, 105, 271–274.10.1002/(ISSN)1096-8628
  • Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., & Farde, L. (1999). Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. American Journal of Psychiatry, 156, 869–875.
  • Sachar, E. J., Gruen, P. H., Altman, N., Halpern, F. S., & Frantz, A. G. (1976). Use of neuroendocrine techniques in psychopharmacological research. In E. J. Sachar (Ed.), Hormones, behavior, and psychopathology (pp. 161–161). New York, NY: Raven Press.
  • Spina, E., DʼArrigo, C., Migliardi, G., Morgante, L., Zoccali, R., Ancione, M., & Madia, A. (2004). Plasma risperidone concentrations during combined treatment with sertraline. Therapeutic Drug Monitoring, 26, 386–390.10.1097/00007691-200408000-00008
  • Young, R. M., Lawford, B. R., Barnes, M. Burton, S. C. Ritchie, T. Ward, W. K., & Noble, E. P. (2004). Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British Journal of Psychiatry, 185, 147–151.10.1192/bjp.185.2.147